Price cut leads NICE to back Novo Nordisk’s obesity drug Sax...

Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management.

Merck & Co to repurpose failed obesity drug for NASH

Merck & Co is to pay $10 million to Hanmi to repurpose an obesity drug discarded by Johnson & Johnson, into a therapy for the fatty liver disease known as NASH.

Could GLP-1 drugs treat space headaches? NASA wants to know.

Experts from NASA are keeping a close eye on UK research that tests whether drugs commonly used in diabetes work against raised brain pressure – a painful problem sometimes seen in women wi

Rhythm doesn’t miss a beat as obesity drug clears phase 3 te...

Boehringer adds to obesity alliance with Denmark’s Gubra

Two years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a higher level.

FDA approves PureTech's obesity device Plenity

The FDA has approved PureTech Health’s ‘space occupying’ device Plenity as a new prescription treatment for obesity, setting it up to rival Novo Nordisk in this lucrative market.